Fluence's foundational course is designed for those who want to learn about Psychedelic Harm Reduction and Integration Therapy in clinical practice.

The 6 hours of self paced content is designed for clinicians and healthcare providers

  • On-Demand Course

    a learning experience you can complete at your own pace, anytime

  • Program Cost

    $395 - Includes 6 total hours of APA CE and NYSED CE for Psychologists, Social workers, and LMHC

  • Materials

    video resources, lesson recap pages, references, and self-assessments

  • Course Components

    Introduction to Psychedelic Harm Reduction and Integration Therapy, Introduction to MDMA-assisted Therapy Research, Introduction to Psilocybin-assisted Therapy Research

Instructors

Lead Trainer

Elizabeth Nielson, PhD

Dr. Elizabeth Nielson is a co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson is a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, MDMA-assisted treatment PTSD, and psilocybin-assisted treatment of treatment resistant depression. Through Fluence, she provides continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings. Her program of research includes qualitative and mixed-methods projects designed to further understand the phenomenology and mechanisms of change in psychedelic-assisted therapy, including the experiences of trial participants and of the therapists themselves. Having completed an NIH postdoctoral fellowship at NYU, she has published and presented on topics of psychedelic therapist training, therapists’ personal experience with psychedelics, and including psychedelic integration in group and individual psychotherapy.

Lead Trainer

Ingmar Gorman, PhD

Dr. Ingmar Gorman is a psychologist who specializes in helping people who use psychedelics and other psychoactive compounds. He received his clinical training at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital. He completed his NIH postdoctoral fellowship at New York University in 2017. Dr. Gorman was formerly the Director of the Psychedelic Education and Continuing Care Program at the Center for Optimal Living and is now the co-founder of Fluence, a psychedelic education company training mental health providers in psychedelic treatments. Along with Dr. Paleos, he is currently site co-principal investigator and therapist on a Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder.

Learning Objectives

This Course offers 6 total hours of APA CE and NYSED CE for Psychologists, Social Workers, and LMHCs.

Upon Completion of Introduction to Psychedelic Harm Reduction and IntegrationTM Therapy participants will be able to:

  • Discuss the historical justifications for psychedelic clinical research
  • Describe key theoretical approaches to psychedelic-assisted therapy
  • Discuss the state of psychedelic clinical research, rescheduling efforts, and how psychedelic-assisted psychotherapy works with clients
  • Compare psychedelic integration psychotherapy to integration in peer and shamanic settings
  • Assess clients for key “red flags” that indicate someone should seek specialized psychiatric care after a psychedelic experience
  • Utilize principles of psychedelic-assisted therapy in a basic/initial assessment of clients who report psychedelic use
  • List contraindications and discuss high risk cases of individuals who are contemplating psychedelic use
  • Describe the role of the therapist in an individual's integration psychotherapy process

Upon Completion of Introduction to MDMA-assisted Therapy Research participants will be able to:

  • Name at least two key figures in modern clinical research with MDMA
  • Articulate one reason why MDMA-assisted therapy is thought to be a good fit for treatment of PTSD
  • Explain how current MDMA-assisted therapy combines non-drug psychotherapy sessions with MDMA sessions

Upon Completion of Introduction to Psilocybin-assisted Therapy Research participants will be able to:

  • Name one early model of psychedelic-assisted therapy that informs modern clinical research with psilocybin
  • Identify at least 3 indications for which psilocybin-assisted therapy has been researched in modern clinical trials

Continuing Education

Continuing Education Credits for Health Professionals (CE)

  • Fluence International, Inc. is approved by the American Psychological Association to sponsor continuing education for psychologists. Fluence maintains responsibility for this program and its content.

  • Fluence International, Inc. is recognized by the New York State Education Department’s State Board for Mental Health Practitioners as an approved provider of continuing education for licensed mental health counselors. #MHC-0232.

  • Fluence International, Inc. is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0674.

  • Fluence International, Inc. is recognized by the New York State Education Department's State Board for Psychology as an approved provider of continuing education for licensed psychologists #PSY-0167.

  • The Department’s approval of a provider of continuing education does not constitute the Department’s endorsement of the content, positions or practices that may be addressed in any specific continuing education course offered by the approved provider.

  • For questions about receiving your CE/CME Certificate or Certificate of Attendance, contact Selah Drain, selah@fluencetraining.com.